Navigation Links
New Migraine Drug Shows Promise
Date:11/24/2008

Telcagepant works differently than standard triptans, researchers say

MONDAY, Nov. 24 (HealthDay News) -- A drug called telcagepant proved safe and effective in treating migraines and caused fewer side effects than the widely-used migraine drug zolmitriptan (Zomig), according to a study conducted by drug maker Merck & Co.

Zolmitriptan and other triptans are effective but can cause a number of side effects, including dizziness, tingling and numbness of the skin, chest discomfort, and throat tightness. In addition, triptans cause blood vessel narrowing and aren't recommended for patients with cardiovascular disease, high blood pressure and certain migraine subtypes, according to a news release about the study.

Telcagepant is from a different class, called calcitonin gene-related peptide (CGRP) antagonists. It's believed that brain concentrations of CGRP are elevated during a migraine. CGRP antagonists don't seem to have blood vessel narrowing properties and, therefore, may not carry the same cardiovascular-related risks as triptans.

This phase III study included 1,380 patients at 81 sites in Europe and the United States. The patients, who suffered from moderate or severe migraines, received either 150 milligrams or 300 milligrams of telcagepant, 5 milligrams zolmitriptan, or a placebo.

The 300-milligram dose of telcagepant was more effective than placebo for freedom from pain (27 percent of patients vs. 10 percent), pain relief (55 percent vs. 28 percent), absences of noise sensitivity (58 percent vs. 37 percent) and light sensitivity (51 percent vs. 29 percent), and nausea (65 percent vs. 55 percent), according to the study.

Telcagepant 300 milligram and zolmitriptan 5 milligram were similarly effective in treating migraines, and both were more effective than telcagepant 150 milligram. Negative side effects were reported by 31 percent of patients taking telcagepant 150 milligram, 32 percent taking placebo, 37 percent taking telcagepant 300 milligram, and 51 percent taking 5 milligram zolmitriptan.

"One potential benefit of the new CGRP receptor antagonist class of acute migraine treatments is the absence of vasoconstriction, a liability of the triptans, which may allow for the safe administration of telcagepant in patients with migraine with cardiovascular disease," the study authors wrote. "However, such patients were excluded from the present study because of the contraindication for zolmitriptan, and further studies are necessary to determine the safety of telcagepant in patients with cardiovascular disease. Additional studies are also necessary to assess the long-term efficacy and safety profile of telcagepant in patients treating more than one migraine attack."

The study was published online Nov. 25 and in an upcoming print issue of The Lancet. Preliminary results from the trial were presented in June at the American Headache Society's annual meeting, in Boston.

"This result marks a new era in migraine therapy. However, the remaining issue is to understand the site of action of the CGRP-receptor antagonists," Dr. Lars Edvinsson, of Lund University in Sweden, wrote in an editorial comment accompanying The Lancet study.

More information

The American Academy of Neurology has more about migraine treatments.



-- Robert Preidt



SOURCE: The Lancet, news release, Nov. 25, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Neuromuscular Dentistry Ends Womans Migraines
2. Migraine Tied to Thickening in Brain Area
3. Business Coalition Honors BlueChoice HealthPlan for Migraine Program
4. The HealthCentral Network Wins eHealthcare Awards for Breast Cancer and Migraine Web Sites
5. MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine
6. Comatose locusts may help relieve migraines
7. Epilepsy Drug Doesnt Prevent Migraines
8. MyMigraineConnection.com and Migraine Expert Teri Robert Announce Seventh Annual Migraine and Headache Poetry Contest
9. Migraines Frequency Influences Heart Attack, Stroke Risk
10. Overuse of Opioids, Barbiturates Boosts Chronic Migraine Risk
11. Skin Pain, Sensitivity Rises With Migraine
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Migraine Drug Shows Promise
(Date:5/31/2016)... ... 31, 2016 , ... The successful implementation of “lean manufacturing” in various fields ... laboratories have different challenges compared to manufacturing environments. , In order to provide ... TOLEDO has developed the Lean Lab Checklist . This checklist will help users ...
(Date:5/31/2016)... ... May 31, 2016 , ... In ... can describe personality traits in humans. Using presidential candidate Donald Trump as an ... vitality. , “AstroNumerology is not about adding numbers up,” says Kalsi. “It ...
(Date:5/31/2016)... ... ... Phynd Technologies, Inc. announced recently the signing of three new hospitals: Meadows ... Center – Somers Point, NJ. The new clients range in bed size from 57 ... Phynd’s solution and its interoperability. , Houston Methodist is a leading academic medical center ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... Dr. Charles ... and Dentistry of New Jersey in the class of 1986, where he graduated in ... dentistry at his current location in Livingston since 1989. He has been a member ...
(Date:5/31/2016)... Washington, NY (PRWEB) , ... May 31, 2016 , ... ... other essential nutrients to on the go individuals and dedicated athletes, continues to transform ... , Loaded with whey, pea and milk protein, branched-chain amino acids (BCAA), alkaline ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... RnRMarketResearch.com adds "Asthma - Pipeline ... of Asthma therapy at various stages, therapeutics assessment by ... (RoA) and molecule type, along with latest updates, and ... players involved in the therapeutic development for Asthma and ... Complete report on H1 2016 pipeline review of Asthma ...
(Date:5/30/2016)... 2016 According to ... Market by Technology (Single-factor (Fingerprint, Face, Iris, ... (Workforce Management), End User (Hospitals, Healthcare Institutions) ... MarketsandMarkets, the market is projected to reach ... 1,182.6 Million by 2016, at a CAGR ...
(Date:5/30/2016)... May 30, 2016 The ... USD 7.3 billion by 2024, according to a ... increasing natality rate, the growing malnutrition coupled with ... and gastro-intestinal tract diseases are expected to boost ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ...
Breaking Medicine Technology: